Here are the DEF 14A proxy statements from CONMED Corporation (CNMD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CNMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNMD filings page.
CONMED Corporation is asking stockholders to vote at its 2026 virtual annual meeting on three items: electing seven directors, approving an advisory say‑on‑pay vote and ratifying PricewaterhouseCoopers as auditor for 2026.
Management highlights 2025 revenue of $1.375 billion, up 5.2%, with orthopedics sales up 5.5% and general surgery up 4.7% in constant currency, driven by platforms such as AirSeal and Buffalo Filter. The Board suspended the quarterly dividend effective October 31, 2025 and expanded authorization for a $150 million share repurchase program while exiting gastroenterology product lines to focus on minimally invasive surgery, smoke evacuation and orthopedic soft tissue repair.
The proxy details leadership changes, including the January 2025 promotion of Pat Beyer to President and CEO and ongoing CFO succession, as well as significant Board refreshment, an independent Chair structure, director term limits and enhanced stock ownership and clawback policies. Executive and director pay programs emphasize performance‑based incentives, relative total shareholder return, and strong alignment with stockholders.